Characteristics of 91 patients with RA and 79 patients with axSpA
| RA (n=91) | SpA (n=79) | |
| Sex, N (%), male | 16 (17.6) | 44 (55.7) |
| Age, mean (SD), years | 49.0 (13.1) | 41.4 (10.2) |
| BMI, mean (SD), kg/m² | 24.7 (4.3) | 25.0 (4.6) |
| Disease duration, mean (SD), years | 10.2 (8.6) | 10.4 (8.9) |
| Work status, N (%), employed | 64 (70.0) | 65 (82.3) |
| Of whom, Manual work | 3 (4.7) | 2 (3.1) |
| Studies > high school, N (%) | 74 (81.3) | 68 (86.1) |
| Functional Comorbidity Index (range, 1–18), mean (SD) | 1.6 (0.9) | 1.4 (0.9) |
| mHAQ, mean (SD) | 0.2 (0.4) | 0.3 (0.3) |
| Ongoing treatment | ||
| NSAIDs, N (%) | 18 (19.8) | 48 (60.8) |
| Glucocorticoids, N (%) | 24 (26.4) | 1 (1.3) |
| Conventional synthetic DMARDs | 85 (93.4) | 17 (21.5) |
| Of whom,Methotrexate, N (%) | 75 (88.2) | 13 (76.5) |
| Biological therapy | 42 (46.0) | 48 (60.8) |
| Of whom,anti-TNF, N (%) | 27 (64.0) | 48 (100) |
| Stability of the treatment over the 3 months prior to inclusion, N (%) | 66 (75.0) | 50 (65.8) |
Percentages are calculated on all complete data.
axSpA, axial spondyloarthritis; BMI, body mass index; DMARDs, disease-modifying antirheumatic drugs; mHAQ, modified Health Assessment Questionnaire27; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor